Compare OPEN & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPEN | LIVN |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2020 | 2015 |
| Metric | OPEN | LIVN |
|---|---|---|
| Price | $3.50 | $78.68 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $1.67 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 37.4M | 660.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $4,371,000,000.00 | N/A |
| Revenue This Year | $3.04 | $9.79 |
| Revenue Next Year | $53.82 | $6.63 |
| P/E Ratio | ★ N/A | $33.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $48.82 |
| 52 Week High | $10.87 | $85.76 |
| Indicator | OPEN | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 47.40 |
| Support Level | $3.21 | $74.99 |
| Resistance Level | $3.75 | $81.83 |
| Average True Range (ATR) | 0.20 | 2.64 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 37.34 | 52.68 |
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital-light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.